| Literature DB >> 17485243 |
Salvatore Pepe1, Silvana F Marasco, Steven J Haas, Freya L Sheeran, Henry Krum, Franklin L Rosenfeldt.
Abstract
In this review we summarise the current state of knowledge of the therapeutic efficacy and mechanisms of action of CoQ(10) in cardiovascular disease. Our conclusions are: 1. There is promising evidence of a beneficial effect of CoQ(10) when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-centre prospective randomised trials are indicated in all these areas but there are difficulties in funding such trials. 3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17485243 DOI： 10.1016/j.mito.2007.02.005
Source DB: PubMed Journal: Mitochondrion ISSN： 1567-7249 Impact factor: 4.160